Alpha-1D adrenergic receptor
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Alpha-1D adrenergic receptor as ChEMBL target CHEMBL326, mapped to UniProt P23944. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why Alpha-1D adrenergic receptor matters
Alpha-1D adrenergic receptor is reviewed as Alpha-1D adrenergic receptor (UniProt P23944); the current evidence base includes 19 approved drugs, 946 compounds, and 115 assays, with lead potency reaching pChEMBL 10.7.
Alpha-1D adrenergic receptor Sequence length is 561 aa.
Review this target as Alpha-1D adrenergic receptor, mapped to UniProt P23944. Sequence length is 561 aa.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 19 approved drugs, 946 compounds, and 115 assays for this target. The dominant activity type is KI. CHEMBL13856 is the current potency anchor at pChEMBL 10.7.
Use CHEMBL13856 as the tractability anchor when discussing potency (pChEMBL 10.7).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why Alpha-1D adrenergic receptor matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract behind UniProt P23944, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL13856
|
10.7 | Kd | — |
|
|
No preferred name
CHEMBL217469
|
10.7 | Kd | — |
|
|
No preferred name
CHEMBL2153423
|
10.6 | Kd | — |
|
|
No preferred name
CHEMBL268758
|
10.6 | Kd | — |
|
|
No preferred name
CHEMBL836
|
10.6 | Kd | Approved |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
ALFUZOSIN
CHEMBL709
|
2003 |
|
|
NAFTOPIDIL
CHEMBL142635
|
1999 |
|
|
TAMSULOSIN
CHEMBL836
|
1997 |
|
|
SERTINDOLE
CHEMBL12713
|
1996 |
|
|
DOXAZOSIN
CHEMBL707
|
1990 |
|
|
TERAZOSIN
CHEMBL611
|
1987 |
|
|
OXYMETAZOLINE
CHEMBL762
|
1986 |
|
|
PRAZOSIN
CHEMBL2
|
1976 |
|
|
PHENTOLAMINE
CHEMBL597
|
1952 |
|
|
PHENYLEPHRINE
CHEMBL1215
|
1952 |
|
|
NOREPINEPHRINE
CHEMBL1437
|
1950 |